elinzanetant (Lynkuet)
Jump to navigation
Jump to search
Indications
- vasomotor symptoms of menopause* (FDA-approved)[4]
- improves sleep disturbances & menopause-related quality of life*
* elinzanetant with greater reduction in vasomotor symptom frequency & severity & improved sleep quality vs fezolinetant[2]
Dosage
Adverse effects
- headache & fatigue most common (7-9% vs 2.5-2.6% for placebo)
- no serious adverse effect in clinical trial[1]
Mechanism of action
- selective neurokinin-1,3 receptor antagonist
More general terms
References
- ↑ 1.0 1.1 Pinkerton JV, Simon JA, Joffe H et al Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause. OASIS 1 and 2 Randomized Clinical Trials. JAMA. Published online August 22, 2024. PMID: https://pubmed.ncbi.nlm.nih.gov/39172446 https://jamanetwork.com/journals/jama/fullarticle/2822766
- ↑ 2.0 2.1 Menegaz de Almeida A, Oliveira P, Lopes L, et al. Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis. Obstet Gynecol. 2025 Jan 2 PMID: https://pubmed.ncbi.nlm.nih.gov/39746208
- ↑ Panay N, Joffe H, Maki PM, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 8:e254421 PMID: https://pubmed.ncbi.nlm.nih.gov/40920404 PMCID: PMC12418220
- ↑ 4.0 4.1 Monaco K Novel Nonhormonal Drug Approved for Menopause Hot Flashes. Elinzanetant is the first dual neurokinin targeted therapy for this indication. MedPage Today October 24, 2025 https://www.medpagetoday.com/obgyn/menopause/118141